Results 141 to 150 of about 964 (170)

Olodaterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease

Drugs, 2015
Olodaterol (Striverdi(®) Respimat(®)) is an inhaled long-acting β2-adrenoceptor agonist (LABA) indicated as a once-daily maintenance bronchodilator therapy in adults with COPD. Several well-designed phase III trials have assessed use of the drug over 6 or 48 weeks in this patient population.
openaire   +2 more sources

Tiotropium Bromide/Olodaterol as Maintenance Treatment for Patients with COPD

Clinical Medicine Reviews in Vascular Health, 2016
Chronic obstructive pulmonary disease (COPD) requires appropriate treatment regimens, since it is a major cause of morbidity and mortality worldwide. Recently, several clinical trials confirmed that compared with tiotropium monotherapy and combination therapy of long-acting β2 agonist (LABA) plus inhaled corticosteroids (ICSs), maintenance therapy with
openaire   +1 more source

Olodaterol hydrochloride

Drugs of the Future, 2013
null Cazzola, M., null Matera, M.G.
openaire   +1 more source

Olodaterol/tiotropium-bromide

Reactions Weekly, 2020
openaire   +1 more source

Olodaterol/tiotropium bromide

Reactions Weekly, 2019
openaire   +1 more source

New Drugs: Dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate

Journal of the American Pharmacists Association, 2015
Daniel A, Hussar, Dean R, Wetty
openaire   +2 more sources

Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium + olodaterol

Current Medical Research and Opinion, 2021
Gérard Criner
exaly  

Tiotropium + olodaterol shows clinically meaningful improvements in quality of life

Respiratory Medicine, 2015
Dave Singh, Leif Bjermer, Gary Ferguson   +2 more
exaly  

OLODATEROL *

2015
openaire   +1 more source

The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta‐analysis

British Journal of Clinical Pharmacology, 2017
Chang-Hoon Lee, Hyung-Jun Kim, Hyun Woo Lee   +2 more
exaly